Slides: The urgency to treat LDL C post MI: The role of PCSK9 Monoclonal antibodies in reaching goals
Slides as educational service to PACE members and meeting participants.
This lecture by Derek Connolly was part of a EBAC-accredited symposium "Redefining intensive LDL-c management in high CV risk patients - The case for combination therapy" held during ESC Congress 2021.
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: